In animal models of CVD, targeting the NLRP3 inflammasome has shown promise in reducing atherosclerosis and myocardial damage.129 However, translating these findings to humans has proven challenging, as exemplified by the halted phase II trial of MCC950 in rheumatoid arthritis patients due to hepatotoxicity.130. This evidence concerns the gene NLRP3 and atherosclerosis.